← Eichor
Condition: Acute Myeloid Leukemia With Gene Mutations Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Acute Myeloid Leukemia With Gene Mutations

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT07019155Digital PCR of CHIP and MR for MRD Monitoring After Allo-HSCT in AML
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT07500441Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 7 location(s) · Nerviano Medical Sciences · NCT06549790Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Phase 2 · 3 location(s) · M.D. Anderson Cancer Center · NCT03383575Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation
NA · 23 location(s) · Institut Claudius Regaud · NCT05983991A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia
Phase 1/Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07028073a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07007949Study of Families With an Hemopathies Predisposition Related to the DDX41 Gene.
NA · 5 location(s) · Institut Claudius Regaud · NCT06022016A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax,
Phase 1 · 44 location(s) · Kura Oncology, Inc. · NCT05735184Revumenib in Combination With 7+3 + Midostaurin in AML
Phase 1 · 2 location(s) · Richard Stone, MD · NCT06313437Personalized NK Cell Therapy in CBT
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02727803Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensiv
Phase 2 · 1 location(s) · Technische Universität Dresden · NCT06696183A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leuke
Phase 3 · 253 location(s) · Janssen Research & Development, LLC · NCT06852222Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML
Phase 2 · 18 location(s) · Technische Universität Dresden · NCT05904106Oral-ATO for TP53-mutated Myeloid Malignancies
Phase 2 · 1 location(s) · The University of Hong Kong · NCT06778187MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05735717Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutati
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03683433A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed A
Phase 3 · 205 location(s) · Children's Oncology Group · NCT04293562CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04493164Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
Phase 2 · 1 location(s) · yuejun Liu · NCT07012447A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Phase 1/Phase 2 · 57 location(s) · Syndax Pharmaceuticals · NCT04065399A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05756777Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated
Phase 1 · 23 location(s) · Lomond Therapeutics Holdings, Inc. · NCT06366789
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.